Sarcosine

Sarcosine

SCHEMBL272983

CNCC(=O)O.NCC(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Sarcosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA1 P23415 1/20 0.56
SLC6A9 P48067 1/20 0.56
OR51E2 Q9H255 1/20 0.56
EGLN1 Q9GZT9 4/20 0.37
KDM4E B2RXH2 4/20 0.37
KDM5C P41229 2/20 0.37
PHF8 Q9UPP1 2/20 0.37
KDM2A Q9Y2K7 2/20 0.37
CTH P32929 1/20 0.37
GABRR1 P24046 2/20 0.36
APEX1 P27695 1/20 0.35
LDHA P00338 1/20 0.35
SRR Q9GZT4 1/20 0.35
LMNA P02545 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
PTGS2 P35354 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
FFAR3 O14843 1/20 0.33
KDM6B O15054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sarcosine SCHEMBL2188433 0.89 GLRA1 (0.40) GLRA1SLC6A9OR51E2EGLN1KDM4E
Sarcosine SCHEMBL26641423 0.88 LDHA (0.44) GLRA1SLC6A9OR51E2EGLN1KDM4E
Sarcosine SCHEMBL31427574 0.88
Sarcosine SCHEMBL156329 0.88 LDHA (0.44) GLRA1SLC6A9OR51E2EGLN1KDM4E
Sarcosine SCHEMBL149 0.88
Sarcosine SCHEMBL28259932 0.88
Sarcosine SCHEMBL10395802 0.87 GLRA1 (0.42) GLRA1SLC6A9OR51E2GABRR1LMNA
Sarcosine SCHEMBL4962879 0.86 CTH (0.39) GLRA1SLC6A9OR51E2EGLN1KDM4E
Sarcosine SCHEMBL25435381 0.85
Sarcosine SCHEMBL16162573 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4375377-A1 SUBSTANCE DETECTION METHOD USING AMINOACYLASE Josho Gakuen Educational Foundation (JP) 2024-05-29 EP disclosed
US-20240060080-A1 SYNTHETIC DESALINATION GENETIC CIRCUIT IN PLANTS UNIV COLORADO STATE RES FOUND (US) 2024-02-22 US disclosed
CN-117425733-A Substance detection method using acylated amino acid hydrolase 学校法人常翔学园 2024-01-19 CN disclosed
US-20230390250-A1 MODULATION OF GLUCAGON-LIKE PEPTIDE 1 AND USES THEREOF DUNCAN ROBIN ELAINE (CA) 2023-12-07 US disclosed
US-20230220443-A1 CHARACTERIZATION OF S-ADENOSYL-L-METHIONINE-CONSUMING ENZYMES WITH 1-STEP EZ-MTASE: A UNIVERSAL COUPLED-ASSAY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-13 US disclosed
US-11692199-B2 Synthetic desalination genetic circuit in plants COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2023-07-04 US disclosed
WO-2023002821-A1 SUBSTANCE DETECTION METHOD USING AMINOACYLASE 学校法人常翔学園 2023-01-26 WO disclosed
CN-113263812-B Laminate for battery outer package, and battery 藤森工业株式会社 2022-11-29 CN disclosed
US-20220213040-A1 CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE H. LUNDBECK A/S (DK) 2022-07-07 US disclosed
WO-2022087749-A1 MODULATION OF GLUCAGON-LIKE PEPTIDE 1 AND USES THEREOF DUNCAN ROBIN ELAINE (CA) 2022-05-05 WO disclosed
US-6083913-A TREATING BLOOD DISORDERS GLAXO WELLCOME INC. (US) 2000-07-04 US disclosed
WO-2000011142-A2 METHYLTRANSFERASES, NUCLEIC ACID MOLECULES ENCODING METHYLTRANSFERASES, THEIR RECOMBINANT EXPRESSION AND USES THEREOF DANISCO FINLAND OY (FI) 2000-03-02 WO disclosed
EP-0861264-A2 COLLAGEN-LIKE PEPTOID RESIDUE-CONTAINING STRUCTURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-09-02 EP disclosed
WO-1997019106-A2 COLLAGEN-LIKE PEPTOID RESIDUE-CONTAINING STRUCTURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-05-29 WO disclosed
US-5091561-A Oxidation of N-phosphonamethyliminodiacetic acid using molecular oxygen and transition metal catalyst MONSANTO COMPANY (US) 1992-02-25 US disclosed
US-4965402-A CATALYTIC OXIDATION OF N-PHOSPHONOMETHYLIMINODIACETIC ACID MONSANTO COMPANY (US) 1990-10-23 US disclosed
US-4853159-A COBALT CATALYTIC OXIDATION OF N-PHOSPHONOMETHYLIMINODIACETIC ACID MONSANTO COMPANY (US) 1989-08-01 US disclosed
US-4353983-A ELECTROCHEMISTRY BATTELLE MEMORIAL INSTITUTE (CH) 1982-10-12 US disclosed
EP-0020623-A1 ANALYTICAL PROCESS AND MEANS FOR MEASURING THE AMOUNT OF HYDROGEN PEROXIDE IN AQUEOUS MEDIA AND OF ORGANIC SUBSTRATES GENERATING HYDROGEN PEROXIDE BY ENZYMATIC OXIDATION. BATTELLE MEMORIAL INSTITUTE (CH) 1981-01-07 EP disclosed
WO-1980001081-A1 ANALYTICAL PROCESS AND MEANS FOR MEASURING THE AMOUNT OF HYDROGEN PEROXIDE IN AQUEOUS MEDIA AND OF ORGANIC SUBSTRATES GENERATING HYDROGEN PEROXIDE BY ENZYMATIC OXIDATION BATTELLE MEMORIAL INSTITUTE (CH) 1980-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213040-A1 CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE COMT, CHAT, SLC6A2 GLRA1 2888/4885SLC6A9 958/4885OR51E2 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.